{
    "info": {
        "nct_id": "NCT04246047",
        "official_title": "DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma",
        "inclusion_criteria": "* Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.\n* Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Must have at least 1 aspect of measurable disease, defined as one of the following;\n\n  1. Urine M-protein excretion >=200 mg per 24-hour, or\n  2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or\n  3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).\n* All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Intolerant to daratumumab.\n* Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).\n* Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.\n* Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.\n* Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.\n* Prior allogenic stem cell transplant.\n* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.\n* Corneal epithelial disease.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic_standard",
                            "expected_value": "International Myeloma Working Group (IMWG) criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.",
            "criterions": [
                {
                    "exact_snippets": "Previously treated with at least 1 prior line of multiple myeloma (MM) therapy",
                    "criterion": "prior lines of multiple myeloma therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have documented disease progression during or after their most recent therapy",
                    "criterion": "disease progression after most recent therapy",
                    "requirements": [
                        {
                            "requirement_type": "timing of progression",
                            "expected_value": [
                                "during most recent therapy",
                                "after most recent therapy"
                            ]
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have at least 1 aspect of measurable disease, defined as one of the following;",
            "criterions": [
                {
                    "exact_snippets": "Must have at least 1 aspect of measurable disease",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "aspect"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Urine M-protein excretion >=200 mg per 24-hour, or",
            "criterions": [
                {
                    "exact_snippets": "Urine M-protein excretion >=200 mg per 24-hour",
                    "criterion": "urine M-protein excretion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24-hour"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or",
            "criterions": [
                {
                    "exact_snippets": "Serum M-protein concentration >=0.5 grams per deciliter (g/dL)",
                    "criterion": "serum M-protein concentration",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).",
            "criterions": [
                {
                    "exact_snippets": "involved FLC level >=10 mg per dL (>=100 mg per liter)",
                    "criterion": "involved serum free light chain (FLC) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mg/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "an abnormal serum free light chain ratio (<0.26 or >1.65)",
                    "criterion": "serum free light chain ratio",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 0.26,
                                        "unit": ""
                                    },
                                    {
                                        "operator": ">",
                                        "value": 1.65,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.",
            "criterions": [
                {
                    "exact_snippets": "All prior treatment-related toxicities ... must be <=Grade 1 at the time of enrollment, except for alopecia.",
                    "criterion": "prior treatment-related toxicities (NCI-CTCAE v5.0)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception to toxicity severity requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing Grade 2 or higher peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Ongoing Grade 2 or higher ... neuropathic pain",
                    "criterion": "neuropathic pain",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corneal epithelial disease.",
            "criterions": [
                {
                    "exact_snippets": "Corneal epithelial disease",
                    "criterion": "corneal epithelial disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogenic stem cell transplant.",
            "criterions": [
                {
                    "exact_snippets": "Prior allogenic stem cell transplant.",
                    "criterion": "allogenic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.",
                    "criterion": "anti-BCMA therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).",
            "criterions": [
                {
                    "exact_snippets": "Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment)",
                    "criterion": "refractoriness to anti-CD38 therapy",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "daratumumab",
                                "any other anti-CD38 therapy"
                            ]
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intolerant to daratumumab.",
            "criterions": [
                {
                    "exact_snippets": "Intolerant to daratumumab",
                    "criterion": "daratumumab intolerance",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Intolerant to bortezomib",
                    "criterion": "bortezomib intolerance",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment)",
                    "criterion": "bortezomib refractoriness",
                    "requirements": [
                        {
                            "requirement_type": "progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to bortezomib (defined as progressive disease ... or within 60 days of completing that treatment)",
                    "criterion": "bortezomib refractoriness",
                    "requirements": [
                        {
                            "requirement_type": "progressive disease within 60 days of completing bortezomib-containing regimen of 1.3 mg/m^2 twice weekly",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.",
            "criterions": [
                {
                    "exact_snippets": "serious and/or unstable pre-existing medical, psychiatric disorder or other conditions",
                    "criterion": "pre-existing medical, psychiatric disorder or other conditions",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "not serious and stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "including renal, liver, cardiovascular, or certain prior malignancies",
                    "criterion": "renal conditions",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "not serious and stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "including renal, liver, cardiovascular, or certain prior malignancies",
                    "criterion": "liver conditions",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "not serious and stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "including renal, liver, cardiovascular, or certain prior malignancies",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "not serious and stable"
                        }
                    ]
                },
                {
                    "exact_snippets": "including renal, liver, cardiovascular, or certain prior malignancies",
                    "criterion": "prior malignancies",
                    "requirements": [
                        {
                            "requirement_type": "seriousness or stability",
                            "expected_value": "not serious and stable"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}